美通社

2024-11-06 08:30

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present the latest data from two clinical studies of selinexor in two Posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024), taking place on December 7-10, 2024, in San Diego, CA, the United States.

Details on the Posters:
Title: Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase III Bench Study
Publication Number: 4748
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Date: Monday, December 9, 2024
Time: 6:00 PM - 8:00 PM (Eastern time)
           7:00 AM - 9:00 AM, December 10, 2024 (Beijing time)
First Author: Dr. Jin Lu (Peking University People's Hospital)
Corresponding Author: Dr. Jian Hou (Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine)

Title: Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch
Publication Number: 4448
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
Date: Monday, December 9, 2024
Time: 6:00 PM - 8:00 PM (Eastern time)
           7:00 AM - 9:00 AM, December 10, 2024 (Beijing time)
First Author: Dr. Rong Tao (Fudan University Shanghai Cancer Center)
Corresponding Author: Dr. Huiqiang Huang (Sun Yat-Sen University Cancer Center)

About XPOVIO® (selinexor)

XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com 
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com 
Mobile: +86 13062747000

source: Antengene Corporation Limited

【你點睇?】美歐官員今周商俄烏戰爭問題,你認為俄烏戰爭是否正加快步向結束?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
3
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
6
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
7
一本萬利 | 2025年的五個「勿」(有片)
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
10
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
14
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
15
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
16
習近平應約與特朗普通電話,特:冀盡快與習見面
17
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
18
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
19
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
20
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
21
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
22
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
23
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
24
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
25
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
26
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
27
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
28
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
29
特朗普就職 | 特朗普上台後行動列表
30
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

流感高峰期

山今養生智慧

輕鬆護老